Profile: Volcano Corp (VOLC.OQ)

VOLC.OQ on NASDAQ Stock Exchange Global Select Market

20.48USD
1 Aug 2013
Price Change (% chg)

$0.51 (+2.55%)
Prev Close
$19.97
Open
$20.01
Day's High
$20.51
Day's Low
$19.86
Volume
191,285
Avg. Vol
246,099
52-wk High
$30.15
52-wk Low
$16.37

Search Stocks

Volcano Corporation (Volcano), incorporated on January 12, 2000, designs, develops, manufactures and commercializes a range of precision guided therapy tools, including intravascular ultrasound (IVUS), and fractional flow reserve (FFR), products. The Company is facilitating the adoption of functional percutaneous interventional (PCI), in which its FFR technology is used to determine whether or not a stent is necessary, and IVUS is used to guide stent placement and optimization. It markets its products to physicians and technicians who perform PCI procedures in hospitals and to other personnel who make purchasing decisions on behalf of hospitals. Its products consist of multi-modality consoles, which are marketed as stand-alone units or as customized units that can be integrated into a range of hospital-based interventional surgical suites called catheterization laboratories (cath labs). Its consoles have been designed to serve as a multi-modality platform for its phased array and rotational IVUS catheters, FFR pressure wires, image-guided therapy catheters and Medtronic’s Pioneer reentry device. Its IVUS products include single-procedure disposable phased array and rotational IVUS imaging catheters and additional functionality options, such as virtual histology tissue characterization (VH), and ChromaFlo stent apposition analysis.

The Company’s FFR offerings can be accessed through its multi-modality platforms, and it provides FFR-only consoles. Its FFR disposables are single-procedure disposable pressure and flow guide wires used to measure the pressure and flow characteristics of blood around plaque enabling physicians to gauge the plaque’s physiological impact on blood flow and pressure. It is developing additional offerings for integration into the platform, including adenosine-free Instant wave-free ratio FFR (iFR), forward-looking IVUS (FL.IVUS), catheters, ultra-high resolution Focal Acoustic Computed Tomography catheters and ultra-high resolution Optical Coherence Tomography (OCT), systems and catheters. It derives its revenues from two segments: medical and industrial. Its medical segment represents its core business, in which it derives revenues from the sale of its multi-modality and FFR consoles and its IVUS and FFR single-use disposables. Its industrial segment derives revenues related to the sales of micro-optical spectrometers and optical channel monitors by Axsun Technologies, Inc. (Axsun), its wholly owned subsidiary, to telecommunication and industrial companies.

IVUS Products

The Company’s single-use disposable catheters operate and interface with the Company’s family of consoles. It offers both digital and rotational catheters. Its IVUS catheters vary in their principal uses, frequencies, shaft sizes, shaft lengths, guide wire compatibility and distal tip lengths. These differences allow for the use of different catheters in various portions of the vascular system. ChromaFlo stent apposition analysis uses sequential IVUS frames to differentiate circulating blood from stationary or anchored tissue. ChromaFlo can be important when assessing stent placement as the detailed cross-sectional image clearly identifies moving blood inside and outside of the stent lumen, prompting physicians in many cases to expand the stent until all of the blood appears inside of the stent lumen. ChromaFlo can also help with the identification of luminal structures, such as lumen border, bifurcations, dissections, and thrombus. The Company’s VH IVUS product allows read and interpret IVUS images with color-coded identification of plaque composition. In addition, an element of the VH IVUS product provides automatic identification of lumen and vessel borders. This feature enables automated vessel sizing.

FFR Products

The Company’s FFR products consist of pressure and flow consoles and single-procedure disposable pressure and flow guide wires. In addition, its FFR products can be integrated with its s5 family of multi-modality consoles. In addition, it is working on the development of iFR, which is an FFR technology that does not require the administration of adenosine, used to widen blood vessels prior to the procedure.

Product Expansion

The Company’s product pipeline includes Image Guided Therapies, Micro and Thrombectomy Catheters, Forward Looking Imaging (FL.IVUS/FL.ICE), Optical Coherence Tomography (OCT). The VIBE RX catheter is its first image-guided therapy device. IVUS guidance provides balloon dilatation with immediate confirmation of interventional results. It is developing OCT products. Its model OCT systems have been used in several clinical settings in Europe and South America. Its goal is to integrate this OCT functionality directly into its s5i integrated imaging suite of products. Its OCT resolution is able to visualize thin layers of cells covering drug eluting stent struts at follow-up. OCT also does not penetrate the vessel wall, so only measurements within the lumen and the first one to two millimeter of the lumen wall are possible.

Clinical Program

The Company’s clinical studies are post-marketing studies using Food and Drug Administration (FDA)-cleared, as well as its products in providing therapy in markets and indications, such as stent placement and optimization, plaque assessment and therapy guidance in the coronary and carotid arteries. Its clinical studies include Assessment of Dual Anti-Platelet Therapy with Drug-Eluting Stents (ADAPT-DES); Vascular Evaluation for Revascularization; Fractional Flow Reserve and Intravascular Ultrasound Relationship Study (FIRST); Adensonine Vasodilation Independent Stenosis Evaluation (ADVISE); Adenosine Vasodilation Independent Stenosis Evaluation II (ADVISE II), and Evaluation of XIENCE PRIME or XIENCE V versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL).

ADAPT-DES is a multi-center, registry of up to 15,000 consecutive patients with coronary artery disease undergoing stent-assisted PCI. VERDICT is a prospective, global, multicenter study to determine the correlation between FFR and VH IVUS in patients with intermediate coronary lesions. The objectives of this study are to establish the correlation between FFR and VH IVUS-derived parameters. FIRST was a multi-center, prospective registry of patients with intermediate coronary lesions that underwent both VH IVUS and FFR interrogation. ADVISE was a pilot study to assess the ability of an investigational product, iFR, to provide a measurement of the severity of a coronary stenosis. EXCEL is a prospective, unblinded, randomized multi-center trial involving approximately 2,600 patients with left main coronary artery, orULMCA, disease and treatment groups of stenting with XIENCE PRIME or XIENCE V Everolimus Eluting Coronary Stent System versus coronary artery bypass grafting.

The Company competes with Boston Scientific, Inc., Terumo Corporation, St. Jude Medical, Inc., Optoplex Corporation, Aegis Lightwave, Inc. and BaySpec, Inc.

Company Address

Volcano Corp

Suite 200, 3661 Valley Centre Dr
SAN DIEGO   CA   92130
P: +1800.2284728
F: +1858.7200325

Search Stocks